FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose Finding in Phase 1A

Trial Profile

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose Finding in Phase 1A

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Bemarituzumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms FIGHT
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 02 Aug 2018 Planned End Date changed from 30 Jun 2018 to 28 Feb 2019.
    • 02 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 24 Jul 2018.
    • 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top